During the last session, Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s traded shares were 0.57 million, with the beta value of the company hitting 2.08. The 52-week high for the TNXP share is $32.32, that puts it down -6633.33 from that peak though still a striking 12.5% gain since the share price plummeted to a 52-week low of $0.42. The company’s market capitalization is $10.13M, and the average intraday trading volume over the past 10 days was 1.22 million shares, and the average trade volume was 1.91 million shares over the past three months.

Tonix Pharmaceuticals Holding Corp (TNXP) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. TNXP has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 1 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -3.27.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) trade information

Tonix Pharmaceuticals Holding Corp (TNXP) registered a -0.31% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -0.31% in intraday trading to $0.48, hitting a weekly high. The stock’s 5-day price performance is -0.23%, and it has moved by -21.69% in 30 days. Based on these gigs, the overall price performance for the year is -98.43%. The short interest in Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) is 0.43 million shares and it means that shorts have 0.14 day(s) to cover.

Tonix Pharmaceuticals Holding Corp (TNXP) estimates and forecasts

Statistics show that Tonix Pharmaceuticals Holding Corp has outperformed its competitors in share price, compared to the industry in which it operates. Tonix Pharmaceuticals Holding Corp (TNXP) shares have gone down -95.47% during the last six months, with a year-to-date growth rate more than the industry average at 84.13% against 16.10. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 96.20% this quarter and then jump 94.70% in the quarter after that. In the rating firms’ projections, revenue will increase 79.10% compared to the previous financial year.

As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 3.5M as predicted by 3 analyst(s). Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to 3.58M by the end of current fiscal year.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 79.31%. While earnings are projected to return 44.76% in 2024.

TNXP Dividends

Tonix Pharmaceuticals Holding Corp is due to release its next quarterly earnings 2024-Aug-09. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP)’s Major holders

Tonix Pharmaceuticals Holding Corp insiders own 1.40% of total outstanding shares while institutional holders control 2.32%, with the float percentage being 2.35%.

Also, the Mutual Funds coming in first place with the largest holdings of Tonix Pharmaceuticals Holding Corp (TNXP) shares are Fidelity Extended Market Index Fund and Vanguard Total Stock Market Index Fund . Data provided on May 31, 2024 indicates that Fidelity Extended Market Index Fund owns about 348.37 shares. This amounts to just over 2.00 percent of the company’s overall shares, with a $0.17 million market value. The same data shows that the other fund manager holds slightly less at 297.3, or about 1.70% of the stock, which is worth about $0.14 million.